Clinical Trial Update: Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of MBA-P01 in treating glabellar frown lines has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glabellar Frown Lines

Drugs mentioned

• MBA-P01

Snippet

Sponsor: Medytox Korea | Conditions: Glabellar Frown Lines | Phase 3 | Status: COMPLETED